ReShape Lifesciences Inc (HIND)

Currency in USD
14.000
+10.080(+257.14%)
Closed·
13.360-0.640(-4.57%)
·
HIND is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
12.57016.000
52 wk Range
1.870303.248
Key Statistics
Prev. Close
3.92
Open
14.26
Day's Range
12.57-16
52 wk Range
1.87-303.248
Volume
126.61K
Average Volume (3m)
3.49M
1-Year Change
-98.48%
Book Value / Share
37.22
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HIND Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

ReShape Lifesciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

ReShape Lifesciences Inc Company Profile

As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual’s comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in the development of the ReShape Obalon Balloon System, which consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and the Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in Irvine, California.

ReShape Lifesciences Inc Earnings Call Summary for Q4/2024

  • Revenue down 8% to $8M, gross profit fell 9% with 63.2% margin; operating costs cut 42% amid competitive pressures
  • Stock surged 65.58% in regular trading but fell 2.93% after hours; market cap at $1.88M with weak financial health score
  • Cash reserves at $700,000; company focused on cost management and expanding product portfolio through partnerships
  • Pending merger with Viome Therapeutics and asset sale to BI RADS; exclusive distribution agreement with Motion Informatics
  • CEO emphasizes disciplined resource management; CFO highlights 42% reduction in operating costs for 2024
Last Updated: 10/04/2025, 22:10
Read Full Transcript

Compare HIND to Peers and Sector

Metrics to compare
HIND
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x0.0x
PEG Ratio
0.000.000.00
Price/Book
0.0x0.0x0.0x
Price / LTM Sales
0.0x0.0x0.0x
Upside (Analyst Target)
0.0%0.0%0.0%
Fair Value Upside
Unlock0.0%0.0%Unlock

Earnings

Latest Release
May 20, 2025
EPS / Forecast
18.98 / --
Revenue / Forecast
1.11M / --
EPS Revisions
Last 90 days

HIND Income Statement

People Also Watch

0.512
WINT
-0.85%
21.81
SRPT
+7.44%
2.140
VOR
+8.08%
2.53
INMB
+3.27%
0.03
GIBO
-21.76%

FAQ

What Stock Exchange Does ReShape Lifesciences Trade On?

ReShape Lifesciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for ReShape Lifesciences?

The stock symbol for ReShape Lifesciences is "HIND."

What Is the ReShape Lifesciences Market Cap?

As of today, ReShape Lifesciences market cap is 8.35M.

What Is ReShape Lifesciences's Earnings Per Share (TTM)?

The ReShape Lifesciences EPS (TTM) is -96.22.

From a Technical Analysis Perspective, Is HIND a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has ReShape Lifesciences Stock Split?

ReShape Lifesciences has split 11 times.

How Many Employees Does ReShape Lifesciences Have?

ReShape Lifesciences has 18 employees.

What is the current trading status of ReShape Lifesciences (HIND)?

As of 15 Aug 2025, ReShape Lifesciences (HIND) is trading at a price of 14.00, with a previous close of 3.92. The stock has fluctuated within a day range of 12.57 to 16.00, while its 52-week range spans from 1.87 to 303.25.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.